Early RUBY-3 Data Shows Promise for Povetacicept in Glomerulonephritis

Preliminary data from the open-label RUBY-3 trial were presented at the American Society of Nephrology Kidney Week 2023.

Related Keywords

United States ,Emory University School Of Medicine ,Georgia ,American ,James Tumlin ,Jonathan Barratt ,American Society Of Nephrology Kidney Week ,University Of Leicester ,Alpine Immune Sciences ,Nephronet Clinical Trials Consortium ,Georgia Nephrology ,American Society ,Nephrology Kidney Week ,Emory University School ,Nephronet Clinical Trials ,Kidney Week ,Immune Sciences ,Mayer Professor ,Renal Medicine ,Enhanced Dual ,Autoantibody Associated Glomerulonephritis ,Paper Presented ,Autoimmune Glomerulonephritis ,Late Breaking Poster Session ,